Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tepotinib - Merck KGaA

Drug Profile

Tepotinib - Merck KGaA

Alternative Names: EMD-1214063; MSC-2156119; MSC-2156119J

Latest Information Update: 24 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EMD Serono; Merck KGaA; Merck Serono
  • Class Antineoplastics; Nitriles; Piperidines; Pyridazines; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer; Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 20 Nov 2019 Tepotinib receives Orphan Drug status for Non-small cell lung cancer in Japan
  • 17 Oct 2019 Merck KGaA initiates a phase I trial in Healthy volunteers in Germany (PO) (NCT04204902)
  • 16 Sep 2019 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain (PO) (EudraCT2019-001538-33)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top